• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma
In this study, we treated ten patients with newly diagnosed MG with apixaban, 2.5  mg twice daily beginning 2–21 days after craniotomy and continuing for up to 6 months. Unacceptable toxicity was defined by ≥ grade 2 CNS or non-CNS hemorrhage, a thromboembolic event (i.e. stroke) or cardiovascular event requiring anticoagulation or anti-platelet therapy. There were no unacc eptable toxicities to report and no treatment-related adverse events. None of the patients on the study were diagnosed with a VTE while receiving apixaban. We conclude that apixaban can be given safely to patients with primary MG shortly after cra...
Source: Journal of Thrombosis and Thrombolysis - August 4, 2021 Category: Hematology Source Type: research

Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin
Venous thromboembolism occurs in up to one-third of patients with primary brain tumors. Spontaneous intracranial hemorrhage (ICH) is also a frequent occurrence in these patients, but there is limited data on the safety of therapeutic anticoagulation. To determine the rate of ICH in patients treated with enoxaparin, we performed a matched, retrospective cohort study with blinded radiology review for 133 patients with high-grade glioma. After diagnosis of glioma, the cohort that received enoxaparin was 3 times more likely to develop a major ICH than those not treated with anticoagulation (14.7% vs 2.5%; P = .036; hazard rati...
Source: Blood - June 22, 2017 Category: Hematology Authors: Mantia, C., Uhlmann, E. J., Puligandla, M., Weber, G. M., Neuberg, D., Zwicker, J. I. Tags: Free Research Articles, Thrombosis and Hemostasis, Clinical Trials and Observations Source Type: research

Tumor Treating Fields (TTF) with Triple Chemotherapy for Recurrent Glioblastoma (P1.177)
Conclusions:Therapies with TTF plus TBC demonstrates superior OS benefit for recurrent GBM with moderate, but manageable side effects. A prospective study of TTF plus TBC for recurrent GBM is warranted.Study Supported by: Dr. Marnie Rose FoundationDisclosure: Dr. Zhu has received personal compensation for activities with Novocure, and Prime Oncology. Dr. Zhu has received research support from Novocure, Inc., Five Prime Therapeutics, Immuno-Cellular Inc., DEKK-TEC. Dr. Lu has nothing to disclose. Dr. Rao has nothing to disclose. Dr. Zhu has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Zhu, J.-J., Lu, G., Rao, M., Zhu, P. Tags: Neuro-oncology: Gliomas I Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - December 16, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma
The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS...
Source: Neuro-Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Koeppen, S., Hense, J. Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - March 9, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Chapter 15 Vascular complications in glioma patients
Publication date: 2016 Source:Handbook of Clinical Neurology, Volume 134 Author(s): Emilie Le Rhun, James R. Perry Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the...
Source: Handbook of Clinical Neurology - March 4, 2016 Category: Neurology Source Type: research

Cn-14 * retrospective analysis of ischemic cerebral strokes in patients diagnosed with a glioblastoma during the course of a bevacizumab treatment
Bevacizumab is an anti-vascular endothelial growth factor approved in the treatment of recurrent glioblastoma. It prolongs progression-free survival, improes radiologic response and contributes to reduce the dose of dexamethasone required to control peritumoral edema. Arterial and venous thromboembolic events represent significant toxicities related to the use of angiogenesis inhibitors. Various mechanisms could be implicated in bevacizumab-related strokes, as cardioembolic, lacunar stroke related to hypertension, deep venous thrombosis passing through a patent foramen ovale, pro-coagulant effect of the underlying glioblas...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Maurice, C., Mason, W. P. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research

Drugs to be offered to women at high risk of breast cancer
The National Institute of Health and Care Excellence (NICE) has today released updated guidelines on the care of women who are at increased risk of breast cancer due to their family history. One of the main changes to the original guidance from 2004 is that NICE now recommends drug treatment with tamoxifen or raloxifene to reduce risk of breast cancer in a specific group of women who are at high risk of breast cancer and have not had the disease. They say that these treatments could help prevent breast cancer in about 488,000 women aged 35 years and older. The updated guideline has also made changes to the recommende...
Source: NHS News Feed - June 25, 2013 Category: Consumer Health News Tags: Cancer Medical practice QA articles Source Type: news